Myrbetriq (Mirabegron) Patent Expiration, LOE Window & CMS Spending

Myrbetriq (Mirabegron) by Astellas Pharma: FDA Orange Book LOE 2030-03-28, 7 AB generics, $2.41B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstellas Pharma
FDA Application & PathwayN202611 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-03-28
Orange Book Patents (*PED Extensions)10 patents (5 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$2.41B
2024 Medicare Part D Spend$2.30B
2024 Medicaid Spend$108.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.